SRPTShortest Remaining Process Time
SRPTSacramento River Preservation Trust (California)
SRPTSmall Repair Parts Transporter
SRPTSafe Return Personal Trainer (exercise professionals)
SRPTSprint R.P. Telekom (Sprint Poland)
SRPTSaigon Railway Passenger Transport Co. (Vietnam)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
While Mindanao's latest SRPT is a new record-high, all SRPTs in other areas were either unchanged or decreased.
SWS has done national surveys on SRP and SRPT from 1983 to the present.
The Shortest Remaining processing time (SRPT) [5] policy, that prioritizes jobs that require the smallest amount of work to complete, is that the one that minimizes the mean latency (or sojourn time), that's the time that passes between a job submission and its completion.
In the SRPT job schedule, at any instant the number of processed jobs is not smaller than in any other job schedule.
"Using SLDB and PFE's percent dystrophin positive fibers data as a surrogate for transduction efficiency, we model that SLDB could achieve a transduction efficiency in the 40-60% range at their current dosing of 2E14 vg/kg, which, even at the high end of the range, is still considerably inferior to SRPT's ~81%."
In NCR, as of June 2016, P20,000 per month was the median SRPT of the poor.
As of March 2016, the median SRPTs, or the monthly home budgets that would satisfy half of the self-rated poor are P20,000 in the NCR, and an equal P10,000 per month in the Rest of Luzon, Visayas, and Mindanao.
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are tanking Tuesday morning as a binary event turned up a negative outcome for the company.
Morgan Stanley analyst Matthew Harrison raised his price target for Sarepta Therapeutics (SRPT) to $220 from $165 while keeping an Overweight rating on the shares.
* Baird cut Sarepta Therapeutics Inc(NASDAQ: SRPT) price target from $202 to $181.
Sarepta (SRPT), up 2% after Morgan Stanley analyst Matthew Harrison raised his price target for shares to $220 from $165 while keeping an Overweight rating.
Sarepta Therapeutics, Inc.(NASDAQ: SRPT) was down, falling 14% to $103.95 after the company announced it had received a complete response letter from the FDA regarding the new drug application seeking accelerated approval of Golodirsen.